MH
BIO icon

Mason Hawkins’s Bio-Rad Laboratories Class A BIO Stock Holding History

Mason Hawkins’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-162,804
Closed -$45.4M – 48
2026
Q1 		$45.4M Sell
162,804
-64,826
-28% -$18.7M 2.23% 14
2025
Q4 		$69M Sell
227,630
-9,624
-4% -$3M 3.07% 11
2025
Q3 		$66.5M Sell
237,254
-78,031
-25% -$21.2M 3.4% 11
2025
Q2 		$76.1M Sell
315,285
-8,520
-3% -$2.01M 3.84% 9
2025
Q1 		$78.9M Buy
323,805
+15,336
+5% +$4.61M 4.2% 9
2024
Q4 		$101M Sell
308,469
-9,867
-3% -$3.35M 4.78% 8
2024
Q3 		$107M Sell
318,336
-6,677
-2% -$2.12M 5.02% 7
2024
Q2 		$88.8M Sell
325,013
-18,946
-6% -$5.51M 3.87% 9
2024
Q1 		$119M Sell
343,959
-20,099
-6% -$6.61M 4.57% 9
2023
Q4 		$118M Buy
364,058
+37,956
+12% +$11.9M 4.52% 8
2023
Q3 		$117M Buy
326,102
+583
+0.2% +$225K 4.33% 7
2023
Q2 		$123M Buy
+325,519
New +$132M 4.35% 8

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Mason Hawkins's BIO Position: Q2 2026 in Review

Mason Hawkins sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 162,804 shares — an estimated $45.4M sold.

Mason Hawkins first reported a position in BIO in Q2 2023 and held it in 12 quarters. The position peaked at $123M in Q2 2023. 396 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Mason Hawkins reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
  • Mason Hawkins sold 162,804 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $45.4M.
  • Mason Hawkins first reported a position in Bio-Rad Laboratories Class A in Q2 2023 and held it in 12 quarters.
  • Mason Hawkins's Bio-Rad Laboratories Class A position peaked at $123M in Q2 2023.
  • 396 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Southeastern Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.